Grunenthal Says Actavis, Alkem Infringed Painkiller IP

Law360, New York (July 26, 2013, 6:34 PM ET) -- German pharmaceuticals giant Grunenthal GmbH accused rivals Actavis Inc. and Alkem Laboratories Ltd. of infringing patents for its painkiller Nucynta by seeking federal approval for generic copies of the drug, according to a suit filed in New Jersey federal court Thursday.

Actavis and Alkem allegedly violated the three patents by filing abbreviated new drug applications with the U.S. Food and Drug Administration to manufacture and sell tapentadol hydrochloride tablets for pain management before the patents' expiration, Grunenthal said

The generic pharmaceuticals manufacturers have "committed or aided,...
To view the full article, register now.